Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

The Unintended Impact of COVID-19 Associated Non-Pharmaceutical Interventions on Paediatric Hospital Admissions: An Interrupted Time Series Analysis

COVID-19 related non-pharmaceutical interventions (NPIs) disrupted global healthcare utilisation, with notable declines in infection related paediatric hospitalisations. We aimed to identify non-infectious paediatric conditions for which the incidence of hospital admissions increased during the introduction and alleviation of NPIs in 2020.

Research

Statistical considerations for the platform trial in COVID-19 vaccine priming and boosting

The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.

People

Dr Ruth Thornton

Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)

Research

Towards the establishment of the PREVAIL Centre, a Centre for PREcision in VAccine ImpLmentation at The Kids Research Institute Australia

Pat Tom Holt Snelling PhD, DSc, FRCPath, FRCPI, FAA BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher Head, Infectious Disease

Research

Whole-Cell Pertussis Vaccination and Decreased Risk of IgE-Mediated Food Allergy: A Nested Case-Control Study

Australian infants who received whole-cell pertussis vaccines were less likely to be diagnosed with food allergy in childhood

Research

Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children

Atopic diseases are the most common chronic conditions of childhood. The apparent rise in food anaphylaxis in young children over the past three decades is of particular concern, owing to the lack of proven prevention strategies other than the timely introduction of peanut and egg.

Research

The ORVAC trial: A clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis

We hypothesised that scheduling an additional (third) dose of oral human rotavirus vaccine for children aged 6 to <12 months would improve protection

Research

Effectiveness of rotavirus vaccines in an Australian population: A case-control study

RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years

Research

Safety of live attenuated herpes zoster vaccine in adults 70–79 years: A self-controlled case series analysis using primary care data

No new safety concerns were identified for live attenuated herpes zoster vaccine in this study based on a novel, Australian primary care data source